Views & Analysis ‘Quickie divorce’ Brexit not an option for medicines, says U... The UK government wants a 'bespoke' deal for pharma - but the EU has other ideas.
Views & Analysis Will pharma get its own Brexit deal? After the Nissan deal, pharma is looking for similar reassurances
News FDA clears new, safer regimen for Lilly's Alzheimer's drug Eli Lilly has won FDA approval for a new regimen for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of side effects.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
